Newsroom

8 March 2024

Pharma's Almanac: What Strategies Accelerate Time-to-market Without Compromising Quality?

Pharma's Almanac

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss the increasing pressure to reduce time-to-market. The share strategies to accelerate product development and commercialization without compromising quality.

8 March 2024

Pharma's Almanac: How Can Biopharma Demonstrate Its Commitment to ESG in Manufacturing?

Pharma's Almanac

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss how pharmaceutical and biopharmaceutical companies can demonstrate their commitment to ESG principles in manufacturing.

28 February 2024

BioSpace: How Cell and Gene Therapy Manufacturing Will Evolve in 2024

BioSpace

Key figures at Phacilitate’s Advanced Therapies Week emphasized the power of sharing knowledge to create standardized, scalable processes in cell and gene therapy manufacturing. ScaleReady is proud to embrace this approach, especially in our partnership with Luminary Therapeutics.

14 February 2024

Phacilitate: Navigating the Nuances of Process and Analytical Development for Decentralized Production

Phacilitate

Decentralized manufacturing models, where therapies are produced closer to the patient show promise. But the path from research to this decentralized model, while maintaining rigorous Good Manufacturing Practice (GMP) compliance, is anything but easy. In a recent panel discussion, Josh Ludwig shed light on this complex transition.

13 February 2024

The Medicine Maker: The Future of Cell and Gene Therapy Innovation

The Medicine Maker

While cell and gene therapy represent a captivating frontier, ongoing innovation and adaptation to Industry 4.0 principles are essential for progress. In this feature, experts, including Josh Ludwig, Global Director of ScaleReady, delve into the definitions of Industry 4.0 and its implications for the present and future of cell and gene therapy manufacturing.

31 January 2024

Pharma Manufacturing: 2024 Pharma Predictions

Pharma Manufacturing

The upcoming year promises significant changes driven by historic successes and economic challenges in 2023. Notable events mark the industry's current juncture of innovation and adjustment. Industry leaders, including ScaleReady's Josh Ludwig, predict trends for 2024, including the transformative impact of AI in drug development and key regulatory changes to monitor.

31 January 2024

Drug Discovery World: Josh Ludwig Discusses Industry Trends and Predictions for 2024

Drug Discovery World

In this issue of Drug Discovery World, Megan Thomas spoke with industry experts about the opportunities and challenges that lie...

30 January 2024

Drug Discovery World: Challenges Facing Advanced Therapies

Drug Discovery World

During Advanced Therapies Week (ATW) 2024, Drug Discovery World heard from attendees and experts, including ScaleReady's Josh Ludwig, about the obstacles the sector needs to overcome to succeed. 

23 January 2024

APM Health: Automobile-like Production Model Can Cut CAR-T Costs and Ease Patient Access

The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients.

23 January 2024

Scrip Citeline Commercial: What Does 2024 Hold For Biopharma?

Scrips Citeline Commercial

Josh Ludwig joins industry experts in discussing what 2024 has in store for the biopharma industry, including improvements for delivery...

18 December 2023

Genetic Engineering & Biotechnology News: Downstream Trends and Challenges

Genetic Engineering & Biotechnology News

In this Genetic Engineering & Biotechnology News article, "Downstream Trends and Challenges," the author discusses the increasing complexity and challenges facing manufacturers today. ScaleReady is mentioned as a joint venture designed to better serve cell therapy developers with scaleable, flexible platforms from established partners.

15 December 2023

Pharma's Almanac: Significant Regulatory Guidance on the Horizon for 2024

Pharma's Almanac

Pharma's Almanac asked industry experts, including ScaleReady's Global Director Josh Ludwig, their thoughts on the most significant regulatory decisions or guidance on the horizon for 2024. Josh discusses establishing more comprehensive and flexible guidelines for CGTs that will provide the clarity needed to enable creative, high-throughput manufacturing strategies.